27.97
price down icon1.85%   -0.48
 
loading
전일 마감가:
$28.45
열려 있는:
$27.7
하루 거래량:
181.91K
Relative Volume:
0.18
시가총액:
$3.69B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.73%
1개월 성능:
+4.51%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
Value
$27.04
$28.61
1주일 범위
Value
$26.00
$29.50
52주 변동 폭
Value
$12.30
$37.99

Metsera Inc Stock (MTSR) Company Profile

Name
명칭
Metsera Inc
Name
전화
(212) 784-6595
Name
주소
3 WORLD TRADE CENTER, NEW YORK
Name
직원
98
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
MTSR's Discussions on Twitter

MTSR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MTSR
Metsera Inc
28.05 3.69B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
453.71 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
541.42 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.34 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.96 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.76 28.51B 3.81B -644.79M -669.77M -6.24

Metsera Inc Stock (MTSR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-25 개시 BofA Securities Buy
2025-02-25 개시 Evercore ISI Outperform
2025-02-25 개시 Guggenheim Buy

Metsera Inc 주식(MTSR)의 최신 뉴스

pulisher
Jun 17, 2025

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN

Jun 17, 2025
pulisher
Jun 13, 2025

Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 12, 2025

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT - BioSpace

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Metsera stock extends gains on obesity drug data (MTSR:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera’s obesity candidate ‘comparable to leading GLP-1-based medicines’ - The Pharma Letter

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera price target raised to $62 from $56 at Guggenheim - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera CEO to Present Obesity Drug Pipeline at Goldman Sachs Healthcare Conference | MTSR Stock News - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews

Jun 10, 2025
pulisher
Jun 10, 2025

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Jun 10, 2025
pulisher
Jun 09, 2025

Metsera chasing best-in-class profile with amylin program - biocentury.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera reports promising Phase 1 trial results for obesity treatment By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s Amylin Analog Stars In Obesity Phase I - insights.citeline.com

Jun 09, 2025
pulisher
Jun 09, 2025

Obesity treatment startup Metsera rises on positive trial results - Sherwood News

Jun 09, 2025
pulisher
Jun 09, 2025

metsera reports positive phase 1 trial results for obesity drug - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes By Stocktwits - Investing.com India

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera obesity monotherapy data ‘looks competitive,’ says BofA - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera shares climb on early data for amylin-targeting obesity shot - BioPharma Dive

Jun 09, 2025
pulisher
Jun 09, 2025

Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera's Phase 1 Trial of MET-233i Shows Weight Reduction With no Severe Adverse Events - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks - BioSpace

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s drug shows potential in early clinical trial - statnews.com

Jun 09, 2025
pulisher
Jun 09, 2025

metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera shares soar on positive amylin candidate trial results By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera shares soar on positive amylin candidate trial results - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera announces topline data from Phase 1 trial of MET-233i - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Obesity Startup Metsera Shares Rise on Early-Stage Trial Results - Bloomberg.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Metsera’s amylin drug shows early potential for substantial weight loss - statnews.com

Jun 09, 2025
pulisher
Jun 09, 2025

Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Metsera to Present New Research Highlighting the Breadth - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association - TradingView

Jun 05, 2025
pulisher
Jun 05, 2025

Next-Gen Monthly Obesity Drug Shows Promise: Metsera to Present Breakthrough Clinical Data at ADA 2025 - Stock Titan

Jun 05, 2025
pulisher
Jun 02, 2025

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership - insights.citeline.com

Jun 02, 2025

Metsera Inc (MTSR) 재무 분석

Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Metsera Inc 주식 (MTSR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
BERNS PAUL L
Director
Feb 03 '25
Buy
18.00
789,998
14,219,964
8,313,680
ARCH Venture Partners XII, LLC
10% Owner
Feb 03 '25
Buy
18.00
2,222,222
39,999,996
18,503,128
$20.77
price up icon 0.56%
$36.22
price up icon 0.51%
$20.72
price down icon 2.68%
$98.67
price down icon 2.04%
$107.07
price up icon 0.55%
biotechnology ONC
$241.09
price up icon 0.19%
자본화:     |  볼륨(24시간):